Compare Charles River Laboratories Intl. Inc (CRL) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Sunrun Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $287.58 (market cap $13.46B), while Sunrun Inc trades at $9.83 (market cap $2.42B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.6× Sunrun Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| CRL | RUN | |
|---|---|---|
Market Cap | $13.46B | $2.42B |
Sector | Health | Technology |
52-Week High | $282.00 | $21.41 |
52-Week Low | $145.57 | $9.38 |
Enterprise Value | $16.30B | $16.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Sunrun (RUN) trades at $9.79, down 0.81% amid bearish technical signals despite strong earnings beats. The company shows solid profitability with 11.59% net margin and attractive valuation metrics including P/E of 6.82 and P/B of 0.69. Recent Q2 2026 results beat expectations with $0.42 EPS versus $0.23 estimate, though shares declined on reduced full-year guidance and Goldman Sachs price target cut from $18 to $15.
While fundamentals remain strong with growing storage adoption and positive cash generation, near-term headwinds include guidance reductions and solar sector volatility. Analyst consensus remains bullish with $14.38 price target representing 47% upside potential, but investors face execution risks amid the company's shift toward direct sales and competitive market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
